Medicenna Therapeutics Eulerpool News

Medicenna Therapeutics Notizie Azioni

Medicenna Therapeutics è seguito da molti giornalisti e investitori in tutto il mondo. Qui raccogliamo le più recenti notizie Medicenna Therapeutics.

• 13 dicembre ·

  Yahoo
  Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)
• 5 dicembre ·

  Yahoo
  Medicenna Reports Updated Data From ABILITY-1 Trial
• 5 dicembre ·

  Yahoo
  Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study
• 27 novembre ·

  Yahoo
  Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference
• 25 novembre ·

  Yahoo
  Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)
• 15 novembre ·

  Yahoo
  Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update
• 13 novembre ·

  Yahoo
  Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)
• 11 novembre ·

  Yahoo
  Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC
• 8 novembre ·

  Yahoo
  Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
• 15 ottobre ·

  Yahoo
  OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX